ReviewLife (Basel, Switzerland)2021
Endocannabinoid System as Therapeutic Target of PTSD: A Systematic Review.
Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial.Nature medicine · 2026Trial
- PTSD and complex PTSD, current treatments and debates: a review of reviews.British medical bulletin · 2025Review
- Endocannabinoids inhibit contextual fear memory generalization via hippocampal GABAergic synaptic transmission.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Bidirectional Mendelian randomization study reveals interplay between multisite chronic pain and Post-traumatic stress disorder.Scientific reports · 2025Article
- Cannabidiol Modulates Neuroinflammatory Markers in a PTSD Model Conducted on Female Rats.Biomolecules · 2024Article
- Metabotropic Glutamate Receptor 5 as a Potential Biomarker of the Intersection of Trauma and Cannabis Use.The international journal of neuropsychopharmacology · 2024Article
- Childbirth-related posttraumatic stress symptoms - examining associations with hair endocannabinoid concentrations during pregnancy and lifetime trauma.Translational psychiatry · 2023Article
- Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing.Frontiers in pharmacology · 2023Article
- Anxiety sensitivity and cannabis use motives among trauma-exposed young adult cannabis users.The American journal on addictions · 2022Article
- Improved Post-Traumatic Stress Disorder Symptoms and Related Sleep Disturbances after Initiation of Medical Marijuana Use: Evidence from a Prospective Single Arm Pilot Study.Medical cannabis and cannabinoidsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-Traumatic Stress Disorder (PTSD) is a complex disorder involving dysregulation of stress-related hormones and neurotransmitter systems. Research focused on the endocannabinoid system (eCBS) for anxiety and stress regulation, cognitive and emotional responses modulation and aversive memories extinction, leading to the hypothesis that it could represent a possible alternative treatment target for PTSD. In this systematic review, we summarize evidence about the efficacy and safety of medicinal cannabidiol (CBD), Δ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.